Related Research Articles
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.
Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.
Serge Weinberg is a French businessman, and the founder and chairman of Weinberg Capital Partners, an investment firm.
Genzyme was an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme has been a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world’s third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories. Its products are also sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenue with more than 25 products on the market. In 2006 and 2007, Genzyme was named one of Fortune magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America’s leading innovators. In February 2022, Sanofi's new corporate brand was unveiled and former entity "Sanofi Genzyme" got integrated into Sanofi.
Christopher A. Sinclair is an American businessman. He is the chairman of Reckitt, the consumer health and household products company. He is the former chairman and CEO of Mattel, the toy company. Previously, he was chairman and CEO of Pepsi-Cola, the beverage company.
Sheridan Gray Snyder OBE is an entrepreneur, venture capitalist, and philanthropist in the biotechnology industry. He is the founder and CEO of Biocatalyst, but also a "serial entrepreneur", a founder of Genzyme and many other companies. Snyder, who was the University of Virginia's best tennis player when he was studying for his BA in French and Romance Languages there in the 1960s, made "major contributions to the popularisation of tennis in the USA." He co-founded the National Junior Tennis League that reaches 250,000 inner-city young people and constructed a new tennis center at the University of Virginia.
Randall Lynn Stephenson is a retired American telecommunications executive. He served as chairman and chief executive officer (CEO) of AT&T Inc. from May 9, 2007 – June 30, 2020 and as executive chairman of AT&T Inc. from July 1 until December 31, 2020. He served as National President of the Boy Scouts of America from 2016 to 2018. In April 2020, Stephenson announced he would step down as CEO of AT&T effective July 1, 2020, replaced by John Stankey. In November 2020, Stephenson announced he would step down as executive chairman of AT&T effective January 2021, replaced by William Kennard.
Sidney Taurel is an American businessman. He is the chairman of Pearson plc and chairman emeritus of Eli Lilly and Company, where he had a 37-year career and served as chairman and chief executive officer from 1998 to 2008. He became chairman of Pearson in January 2016. He is currently a director of IBM Corporation and advises Almirall S.A. on issues of corporate strategy.
Gordon M. Binder is an American businessman.
Alex Gorsky is an American businessman and the executive chairman of Johnson & Johnson. He is the seventh person who served as chair and chief executive officer of Johnson & Johnson since it became a publicly traded company in 1944. Gorsky stepped down as CEO at Johnson & Johnson in January 2022 and was succeeded by Joaquin Duato.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.
John B. Veihmeyer was global chairman of KPMG from April 2014 till September 2017. He previously served as chairman and chief executive officer of KPMG's U.S. firm for a five-year term from 10 June 2010 until 9 June 2015. William B Thomas, 49, has been elected Chairman of KPMG International. He will lead the KPMG global network of professional services firms for a 4-year term, effective 1 October 2017, succeeding John B Veihmeyer, 61, who is completing his term as Chairman and retiring from the firm, at the end of September 2017.
George S. Barrett is an American business executive in the health care industry. He served as chairman and chief executive officer of Cardinal Health, Inc. from 2009 to 2017. He joined the board of the Columbus Foundation in December 2017.
Olivier Brandicourt is a French business executive and physician, and the former chief executive officer of Sanofi.
Melanie Georgina Lee is an English pharmaceutical industry executive and CEO of LifeArc, succeeding Dave Tapolczay in November 2018.
Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.
Kåre Schultz is a Danish business executive. He was appointed to be chief executive officer of Teva Pharmaceutical Industries in September 2017.
Albert Bourla is a Greek-American veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla served as chief operating officer.
National Resilience, operating primarily as Resilience, is a biomanufacturing and biotechnology company that develops gene therapy, vaccines, viral vectors and other therapeutic protein products. It is headquartered in San Diego, California and has nine additional manufacturing facilities open or in development, including in Missisauga, Boston, the San Francisco Bay Area, North Carolina, Philadelphia, and northern Florida.
References
- 1 2 3 4 5 Christopher Viehbacher – Forbes
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 "Sanofi - Christopher A. Viehbacher". Archived from the original on October 29, 2014. Retrieved October 29, 2014. Sanofi
- 1 2 3 4 5 6 7 8 9 10 Christopher A. Viehbacher | CEO Roundtable on Cancer
- ↑ "Ex-Sanofi CEO talks about his new $2 billion investment fund" . Retrieved 2017-09-13.
- ↑ "Gurnet Point Capital nears deal to acquire drugmaker Innocoll: sources". Reuters. April 4, 2017. Retrieved 2017-09-13.
- 1 2 3 Christopher Viehbacher: Executive Profile & Biography - Businessweek
- ↑ "Drugmaker Sanofi Fires CEO Chris Viehbacher". Business Insider . Retrieved 2020-07-19.